The White House is dropping Heidi Overton’s nomination for commissioner of the Food and Drug Administration amid pressure campaigns by anti-abortion and anti-vaping advocates, according to a White House spokesperson.
The Senate health committee’s chair, Sen. Bill Cassidy (R-Louisiana), had scheduled a vote on her confirmation for Wednesday morning, despite finding difficulty convincing wavering GOP members to support her. Without enough votes to get her nomination through, the White House has decided to back away from her nomination.
Several Republicans on the committee wouldn’t say Tuesday how they planned to vote on Overton’s nomination, including Sens. Lisa Murkowski of Alaska and Josh Hawley of Missouri. Hawley has been under heavy pressure from Marjorie Dannenfelser, the president of SBA Pro-Life America, to oppose Overton unless the Trump administration promises to expedite a thorough review of the abortion pill mifepristone.
But, such promises would have only further repelled the panel’s two Republicans who support abortion rights: Murkowski and Sen. Susan Collins of Maine.
Trending
Overton also faced a barrage of signs set up around Washington over the weekend that read: “Say no to Heidi Vaperton for FDA commissioner.”
The signs were placed by a “private group of citizens who prefer to stay anonymous,” according to the group’s spokesperson, Jenny Kay. The group has a website called “Health in Office” that says it is an “independent consumer watchdog,” but the site doesn’t list any members or donors.
Former White House health adviser Calley Means, a close ally of Health Secretary Robert F. Kennedy Jr., recently castigated Overton in interviews where he said she helped advance vaping industry interests. Activists in Kennedy’s Make America Healthy Again movement similarly dislike Overton, who they view as aligned with the food and drug industries.
Means told The Washington Sun on Tuesday that he isn’t involved in the group behind the signs.
Republicans have only a narrow window to confirm dozens of Trump administration nominees before Democrats take over Congress next year. Without a clear pick to lead the FDA, it could prove extremely difficult to fill the position before Republicans lose the majority.